Bakker Juliet Tammenoms's Net Worth

$533 Million

Who is Bakker Juliet Tammenoms?

Bakker Juliet Tammenoms has an estimated net worth of $533 Million. This is based on reported shares across multiple companies, which include CORCEPT THERAPEUTICS INC, COLLEGIUM PHARMACEUTICAL, INC, Esperion Therapeutics, Inc., Inozyme Pharma, Inc., Lexeo Therapeutics, Inc., Axonics Modulation Technologies, Inc., Vera Therapeutics, Inc., RAPID MICRO BIOSYSTEMS, INC., RxSight, Inc., Tricida, Inc., Talaris Therapeutics, Inc., Sierra Oncology, Inc., Vaxcyte, Inc., 89bio, Inc., Eargo, Inc., Kala Pharmaceuticals, Inc., Venus Concept Inc., Molecular Templates, Inc., Aptinyx Inc., and Aimmune Therapeutics, Inc..

SEC CIK

Bakker Juliet Tammenoms's CIK is 0001431159

Past Insider Trading and Trends

2021 was Bakker Juliet Tammenoms's most active year for acquiring shares with 18 total transactions. Bakker Juliet Tammenoms's most active month to acquire stocks was the month of October. 2014 was Bakker Juliet Tammenoms's most active year for disposing of shares, totalling 26 transactions. Bakker Juliet Tammenoms's most active month to dispose stocks was the month of October. 2023 saw Bakker Juliet Tammenoms paying a total of $22,999,990.00 for 4,838,358 shares, this is the most they've acquired in one year. In 2022 Bakker Juliet Tammenoms cashed out on 3,616,896 shares for a total of $19,498,050.00, their largest year based on trade value.